Cargando…

AddaVax-Adjuvanted H5N8 Inactivated Vaccine Induces Robust Humoral Immune Response against Different Clades of H5 Viruses

Since some cases of human infections with H5N8 avian influenza virus have been reported and caused great concern in recent years, it is important to develop an effective vaccine for human use to prevent a potential H5N8 pandemic. In the present study, a vaccine candidate virus based on newly human-i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Feixia, Liu, Xueying, Dang, Yudong, Duan, Peng, Xu, Wenting, Zhang, Xin, Wang, Shilei, Luo, Jian, Li, Xiuling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612011/ https://www.ncbi.nlm.nih.gov/pubmed/36298548 http://dx.doi.org/10.3390/vaccines10101683

Ejemplares similares

Kinetic of the Antibody Response Following AddaVax-Adjuvanted Immunization with Recombinant Influenza Antigens
por: Ross, Ted. M., et al.
Publicado: (2022)

MPLA and AddaVax(®) Adjuvants Fail to Promote Intramuscular LaAg Vaccine Protectiveness against Experimental Cutaneous Leishmaniasis
por: Oliveira-Maciel, Diogo, et al.
Publicado: (2021)

Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas
por: Mazumder, Suparna, et al.
Publicado: (2022)

Adjuvanted Schistosoma mansoni-Cathepsin B With Sulfated Lactosyl Archaeol Archaeosomes or AddaVax™ Provides Protection in a Pre-Clinical Schistosomiasis Model
por: Perera, Dilhan J., et al.
Publicado: (2020)

The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256
por: van Diepen, Michiel T., et al.
Publicado: (2018)

AddaVax Formulated with PolyI:C as a Potential Adjuvant of MDCK-based Influenza Vaccine Enhances Local, Cellular, and Antibody Protective Immune Response in Mice
por: Nian, Xuanxuan, et al.
Publicado: (2021)

Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2008)

ADDA: a domain database with global coverage of the protein universe
por: Heger, Andreas, et al.
Publicado: (2005)

Intradermal Immunization of SARS-CoV-2 Original Strain Trimeric Spike Protein Associated to CpG and AddaS03 Adjuvants, but Not MPL, Provide Strong Humoral and Cellular Response in Mice
por: Firmino-Cruz, Luan, et al.
Publicado: (2022)

Addition of daptomycin for the treatment of pneumococcal meningitis: protocol for the AddaMAP study
por: Chavanet, Pascal, et al.
Publicado: (2023)

Combined H5ND inactivated vaccine protects chickens against challenge by different clades of highly pathogenic avian influenza viruses subtype H5 and virulent Newcastle disease virus
por: Ali, Ahmed, et al.
Publicado: (2019)

Analysis of total microcystins and nodularins by oxidative cleavage of their ADMAdda, DMAdda, and Adda moieties
por: Foss, Amanda J., et al.
Publicado: (2020)

Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets
por: Cox, Rebecca J., et al.
Publicado: (2015)

AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization
por: Khurana, Surender, et al.
Publicado: (2018)

The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys
por: Muraki, Yuko, et al.
Publicado: (2015)

Emergence and spread of novel H5N8, H5N5 and H5N1 clade 2.3.4.4 highly pathogenic avian influenza in 2020
por: Lewis, Nicola S., et al.
Publicado: (2021)

Cross‐neutralisation of antibodies elicited by an inactivated split‐virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains
por: Höschler, Katja, et al.
Publicado: (2008)

Protective Efficacy of Recombinant Turkey Herpes Virus (rHVT-H5) and Inactivated H5N1 Vaccines in Commercial Mulard Ducks against the Highly Pathogenic Avian Influenza (HPAI) H5N1 Clade 2.2.1 Virus
por: Kilany, Walid H., et al.
Publicado: (2016)

Monoclonal Antibody Targeting Neutralizing Epitope on H5N1 Influenza Virus of Clade 1 and 0 for Specific H5 Quantification
por: He, Fang, et al.
Publicado: (2013)

Heterologous Prime-Boost Vaccination with MF59-Adjuvanted H5 Vaccines Promotes Antibody Affinity Maturation towards the Hemagglutinin HA1 Domain and Broad H5N1 Cross-Clade Neutralization
por: Khurana, Surender, et al.
Publicado: (2014)

Anti-SU Antibody Responses in Client-Owned Cats Following Vaccination against Feline Leukaemia Virus with Two Inactivated Whole-Virus Vaccines (Fel-O-Vax(®) Lv-K and Fel-O-Vax(®) 5)
por: Westman, Mark, et al.
Publicado: (2021)

HealVax
por: Foerster, John, et al.
Publicado: (2018)

To vax or not to vax: Predictors of anti-vax attitudes and COVID-19 vaccine hesitancy prior to widespread vaccine availability
por: Roberts, Hannah A., et al.
Publicado: (2022)

Discrepancies in the efficacy of H5 inactivated avian influenza vaccines in specific-pathogen-free chickens against challenge with the Egyptian H5N8 clade 2.3.4.4 Group B virus isolated in 2018
por: El-Moeid, Amena Abd, et al.
Publicado: (2021)

Inactivated H5 Antigens of H5N8 Protect Chickens from Lethal Infections by the Highly Pathogenic H5N8 and H5N6 Avian Influenza Viruses
por: Jin, Myongha, et al.
Publicado: (2018)

Structural and Antigenic Variation among Diverse Clade 2 H5N1 Viruses
por: Shore, David A., et al.
Publicado: (2013)

Experimental infection and pathology of clade 2.2 H5N1 virus in gulls
por: Gulyaeva, Marina A., et al.
Publicado: (2016)

The Emergence and Decennary Distribution of Clade 2.3.4.4 HPAI H5Nx
por: Antigua, Khristine Joy C., et al.
Publicado: (2019)

Pathogenicity and Transmissibility of Clade 2.3.4.4h H5N6 Avian Influenza Viruses in Mammals
por: Zhang, Cheng, et al.
Publicado: (2022)

Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses
por: Mahmoud, Sara H., et al.
Publicado: (2023)

Novel Clade 2.3.4.4b Highly Pathogenic Avian Influenza A H5N8 and H5N5 Viruses in Denmark, 2020
por: Liang, Yuan, et al.
Publicado: (2021)

Preclinical immunogenicity assessment of a cell-based inactivated whole-virion H5N1 influenza vaccine
por: Zhang, Zhegang, et al.
Publicado: (2022)

Safety, Humoral and Cell Mediated Immune Responses to Two Formulations of an Inactivated, Split-Virion Influenza A/H5N1 Vaccine in Children
por: Chotpitayasunondh, Tawee, et al.
Publicado: (2008)

Novel H5 Clade 2.3.4.4 Reassortant (H5N1) Virus from a Green-Winged Teal in Washington, USA
por: Torchetti, Mia Kim, et al.
Publicado: (2015)

Risk Assessment for Highly Pathogenic Avian Influenza A(H5N6/H5N8) Clade 2.3.4.4 Viruses
por: Bui, Christine H.T., et al.
Publicado: (2021)

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant
por: Chen, Wilbur H., et al.
Publicado: (2014)

VAX Software Overview
por: DELPHI Collaboration
Publicado: (1982)

Central VAX upgrade
Publicado: (1987)

VAX support installation
por: Luque, Maria
Publicado: (2021)

Evaluations for In Vitro Correlates of Immunogenicity of Inactivated Influenza A H5, H7 and H9 Vaccines in Humans
por: Couch, Robert B., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_eaoetnv4s19ck6jkejuf6a5bf1